Oxidative stress and immunosenescence: therapeutic effects of melatonin

Oxid Med Cell Longev. 2012:2012:670294. doi: 10.1155/2012/670294. Epub 2012 Dec 31.

Abstract

Age-associated deterioration in the immune system, which is referred to as immunosenescence, contributes to an increased susceptibility to infectious diseases, autoimmunity, and cancer in the elderly. A summary of major changes associated with aging in immune system is described in this paper. In general, immunosenescence is characterized by reduced levels of peripheral naïve T cells derived from thymus and the loss of immature B lineage cells in the bone marrow. As for macrophages and granulocytes, they show functional decline with advancing age as evidenced by their diminished phagocytic activity and impairment of superoxide generation. The indole melatonin is mainly secreted in the pineal gland although it has been also detected in many other tissues. As circulating melatonin decreases with age coinciding with the age-related decline of the immune system, much interest has been focused on melatonin's immunomodulatory effect in recent years. Here, we underlie the antioxidant and immunoenhancing actions displayed by melatonin, thereby providing evidence for the potential application of this indoleamine as a "replacement therapy" to limit or reverse some of the effects of the changes that occur during immunosenescence.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Aging / drug effects*
  • Aging / immunology
  • Animals
  • Antioxidants / pharmacology*
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / immunology
  • Biological Therapy / trends
  • Cellular Senescence / drug effects
  • Humans
  • Immune System / drug effects
  • Immunization
  • Melatonin / pharmacology*
  • Oxidative Stress / drug effects
  • Phagocytosis / drug effects
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology

Substances

  • Antioxidants
  • Melatonin